Insomnia Therapeutics Market (2026 - 2033)

Insomnia Therapeutics Market Summary

The global insomnia therapeutics market size was valued at USD 3.0 billion in 2025 and is projected to grow from USD 3.1 billion in 2026 to USD 4.4 billion by 2033, at a CAGR of 4.9% from 2026 to 2033. The market in North America dominated with a revenue share of 35.4% in 2025. Factors including increasing stress levels, lifestyle changes, and a growing geriatric population are contributing to a higher prevalence of insomnia.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Key Market Trends & Insights

• By type: Benzodiazepines segment held the largest market share of 29.3% in 2025.
• By sales channel: Over-the-counter (OTC) segment held the largest market share of 61.9% in 2025.

Regional Highlights

• Largest regional market: North America (35.4% revenue share, 2025)
• Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
• By country: The U.S. held the largest market share in 2025

Market Size & Forecast

• Market size in 2025: USD 3.0 Billion
• Estimated market size in 2026: USD 3.1 Billion
• Projected market size by 2033: USD 4.4 Billion
• CAGR (2026-2033): 4.9%

According to the National Library of Medicine, about 30% of adult’s exhibit symptoms of insomnia, highlighting an urgent need for effective treatment options. This rising demand has prompted pharmaceutical companies and healthcare providers to innovate and expand their therapeutic offerings, leading to a surge in the market size. As individuals age, they often face a range of health challenges that can disrupt sleep patterns. This demographic shift necessitates tailored therapeutic interventions to address insomnia in older adults, further fueling market demand. The increasing awareness of sleep health, coupled with the availability of various treatment options-both pharmacological and non-pharmacological-has encouraged patients and healthcare providers to seek solutions for sleep disorders, thereby expanding the market landscape.

To learn more about this report, Download Free Sample Report

The introduction of innovative products, such as novel pharmacotherapeutics and digital therapies such as the FDA-approved Somryst app, has transformed the treatment paradigm for insomnia. Moreover, advancements in artificial intelligence and telemedicine offer promising avenues for improving sleep disorder management. The ability to monitor patients remotely and provide timely interventions enhances the therapeutic experience, aligning with the growing preference for personalized and accessible healthcare solutions.

Supportive reimbursement frameworks enhance the affordability of treatment options, making them more accessible to various patient populations. As telehealth services gain traction, particularly in the Asia-Pacific region, there is a heightened opportunity for broader reach and utilization of insomnia therapies. Collectively, these drivers indicate a robust trajectory for the insomnia therapeutics market, positioned for sustained expansion in the forecast period.

Market Dynamics

The global insomnia therapeutics market is driven by the growing prevalence of chronic and acute sleep disorders, increasing awareness about the health effects of poor sleep, and expanding access to diagnosis and treatment. Rising levels of stress, anxiety, depression, aging populations, and lifestyle changes have increased the number of patients seeking medical care for insomnia. The market includes prescription medicines, over the counter sleep aids, and nonpharmacological treatment approaches, with prescription therapies continuing to account for a significant share due to their use in moderate to severe cases. Healthcare providers are placing greater emphasis on individualized treatment based on patient age, underlying health conditions, and risk of long term medicine use. Regulatory agencies continue to encourage the development of therapies with improved safety profiles and lower risk of dependence. In addition, growing adoption of digital health tools and cognitive behavioral therapy for insomnia is supporting integrated care, creating opportunities for pharmaceutical companies to develop therapies that address both symptom management and long term treatment outcomes.

Analyst Perspective

The insomnia therapeutics market is shifting from the use of traditional sedative medicines toward therapies that offer targeted treatment with improved safety and effectiveness. The market is becoming more focused on approved insomnia therapies, continued research in sleep disorders, and the development of medicines with novel mechanisms of action. Increasing regulatory approvals and product launches are expanding the availability of newer treatment options across major healthcare markets. At the same time, ongoing clinical research is improving the understanding of sleep disorders and supporting the development of therapies that address both sleep onset and sleep maintenance. Companies are also investing in neuroscience research and expanding their sleep medicine portfolios through product development and strategic collaborations. These activities are increasing treatment options for patients, supporting broader access to insomnia therapies, and contributing to the steady development of the insomnia therapeutics market.

Type Insights

Based on type, the benzodiazepines segment led the market with the largest revenue share of 29.3% in 2025. Benzodiazepines are useful for insomnia associated with acute stress. It increases sleep duration by 30-90 minutes, decreases sleep latency, and suppresses slow-wave sleep. The higher acceptability of drugs among physicians due to their quick results and easy availability are driving segmental growth. For instance, according to a report published in the National Center for Biotechnology Information (NCBI) in 2024, the U.S. FDA has approved a few of the BZDs such as alprazolam, clobazam, chlordiazepoxide, and others for the effective treatment of insomnia.

Antidepressants are expected to grow lucratively over the forecast period. Drugs such as nefazodone, trazodone, and mirtazapine may also improve subjective sleep ratings compared to placebo or other antidepressants in patients with depression and suffering from insomnia. For instance, the European Medicines Agency (EMA) and Food and Drug Administration (FDA) approved daridorexant has demonstrated sustained efficacy, improving nocturnal sleep parameters, with a favorable safety and tolerability profile. Thus, this segment has been positively increasing with growing awareness among people and acceptance of such antidepressants in treating insomnia.

Sales Channel Insights

Based on sales channel, the over-the-counter (OTC) segment led the market with the largest revenue share of 61.9% in 2025, owing to the increasing number of patients with insomnia. OTC drugs do not require a prescription and are easily available to patients suffering from acute insomnia. For instance, in October 2024, Neurovalens launched Modius Sleep, an FDA-cleared medical device in the U.S., designed to treat chronic insomnia in adults through targeted neurostimulation for improved sleep quality. The emergence of combination therapies that pair OTC medications with prescription drugs or non-pharmacological interventions helps in providing more effective and personalized treatment options for patients with insomnia.

To learn more about this report, Download Free Sample Report

Prescription therapeutics are projected to grow rapidly over the forecast period, fueled by the increasing awareness regarding drugs and their consumption amongst people. Physicians prescribe the prescription drugs after evaluating sleep disturbance patterns and a patient’s history; thereby, its reliance level is higher, and the chances of adverse effects are also less. These factors are likely to help in fostering the market growth of this segment over the forecast period.

Regional Insights

North America dominated the insomnia therapeutics market with the largest revenue share of 35.4% in 2025. Market growth in the region is due to the rising incidence of insomnia disorders, the increase in awareness levels, and high healthcare spending in this region. The American Academy of Sleep Medicine’s (AASM) Sleep Prioritization Survey 2024 highlighted concerns about adults’ sleep quality, revealing that 12% U.S. adults were diagnosed with chronic insomnia, driving insomnia therapeutics and research further. The governments in North America have been involved in creating awareness about the importance of treating insomnia and the available treatment options.

To learn more about this report, Download Free Sample Report

U.S. Insomnia Therapeutics Market Trends

The insomnia therapeutics market in the U.S. held the largest share in the North America region in 2025, owing to the rising awareness programs and R&D facilities for new drug development. For instance, in the U.S., men (13%) were slightly more likely than women (11%) to have been diagnosed with chronic insomnia, as reported by the AASM. Meanwhile, millennials reported the highest rate of chronic insomnia diagnosis (15%). In addition, favorable reimbursement policies, rising stress levels, and a strong clinical pipeline are expected to drive the market growth over the forecast period.

Europe Insomnia Therapeutics Market Trends

Europe insomnia therapeutics market held substantial market share in 2025. Growing awareness of insomnia and the need for effective treatment has prompted educational institutions and healthcare providers to inform the public about sleep disorders. Meanwhile, advancements in drug discovery, including the development of Quviviq by Idorsia, which received FDA approval in 2022, have contributed to market growth. Lifestyle changes and work-related stress have increased the number of individuals seeking remedies for sleep issues. Despite CBT for Insomnia (CBT-I) being the recommended first-line treatment, its adoption varies across Europe, where limited availability and a dominance of hypnotic medications persist. A lack of training among CBT professionals hinders access. To combat this, experts proposed establishing a European CBT-I Academy for standardized training. Effective CBT-I incorporates behavioral and cognitive interventions, and digital treatment options have been advocated for their wide-reaching efficacy.

The insomnia therapeutics market in Germany is expected to grow in the forecast period. Current data indicates that approximately 50% of individuals with insomnia face comorbidities, such as chronic insomnia and depression. Notably, chronic insomnia was not represented in ICD-10, a gap addressed in ICD-11, effective since January 1, 2022, where it is categorized under sleep-wake disorders (code 7A00). Studies show that in Germany, the health status and quality of life of those with sleep disorders are significantly lower than that of the general population.

Asia Pacific Insomnia Therapeutics Market Trends

Asia Pacific insomnia therapeutics market is expected to register the fastest CAGR of 5.8% in the forecast period. Asia Pacific insomnia therapeutics market is anticipated to witness significant growth in the insomnia therapeutics market. Increased stress levels and shift-work sleep disorders are expected to expand the patient base in Asia Pacific. It also contributes to the growing demand for drugs in these economies. Constantly improving healthcare reimbursement policies and FDA approvals have also impacted the market growth in this region. For instance, in July 2024, Simcere Pharmaceutical announced the acceptance of the new drug application for Quviviq in China, an innovative anti-insomnia drug developed with Idorsia, successfully improving daytime functioning.

Japan insomnia therapeutics market is projected to grow at the fastest rate of 7.0% over the forecast period.Increasing awareness of mental health, urbanization, and demanding lifestyles drove demand for insomnia treatments. Factors such as traditional medicine, advancing healthcare infrastructure, and improving policies also contributed. Japan’s aging population, strong economy, and technological innovation further supported market growth, with its advanced economy and high patent registrations facilitating sleep technology development. SUSMED Med CBT-I App developed by SUSMED, Inc. received regulatory approval from the Ministry of Health, Labour and Welfare for treating insomnia patients in Japan.

Key Insomnia Therapeutics Company Insights

Some of the key companies operating in the insomnia therapeutics include Takeda Pharmaceutical Company Limited; VANDA PHARMACEUTICALS; Merck & Co., Inc. These companies are growing their market presence by launching new products, collaborations, and adopting various other strategies.

• Takeda Pharmaceutical Company Ltd. is a Japan-based company that works for the development of insomnia therapeutics products. It also announced a co-promotion agreement with Meiji Seika Pharma Co., Ltd. for their insomnia treatment drug “ROZEREM” in Japan. Thus, using such strategies, it has been able to expand its market revenue share and its presence not only in Japan but also in other countries.

• Merck & Co., Inc. is a U.S.-based company which works for the development of insomnia therapeutics products. It launched its insomnia treatment drug Belsomra (suvorexant), which was the first in a new class of medications called orexin receptor antagonists. This is expected to help it in expanding its portfolio of insomnia treatments and contributing to the growth of the overall insomnia therapeutics market.

Key Insomnia Therapeutics Companies

The following key companies have been profiled for this study on the  insomnia therapeutics market. 

• Takeda Pharmaceutical Company Limited
• VANDA PHARMACEUTICALS
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (Viatris Inc.)
• Sumitomo Pharma Co., Ltd.
• Sanofi
• Paratek Pharmaceuticals, Inc.
• Ebb Therapeutics (Kryo)

Recent Developments

• In December 2024, Shionogi and Nxera Pharma launched QUVIVIQ (daridorexant) in Japan, targeting adults with insomnia as a new treatment option in the quality of life disease area.

• In August 2024, Big Health received FDA clearance for SleepioRx in the U.S., a digital therapeutic designed to treat chronic insomnia using Cognitive Behavioral Therapy for Insomnia (CBT-I).

• In July 2024, the European Medicines Agency’s CHMP recommended extending Slenyto’s use to treat insomnia in children with neurogenetic disorders, addressing significant unmet needs in this patient population.

• In February 2024, Vanda Pharmaceuticals received FDA notification regarding deficiencies in its supplemental NDA for HETLIOZ to treat insomnia, impacting further discussions on labeling and postmarketing requirements.

Global Insomnia Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global insomnia therapeutics market report based on type, sales channel, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Benzodiazepines

  • Nonbenzodiazepines

  • Antidepressants

  • Orexin Antagonists

  • Melatonin Antagonists

  • Others

• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Prescription

  • Over-the Counter (OTC)

• Regional Outlook (Revenue, USD Million; 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • APAC

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The insomnia therapeutics reagents market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each insomnia therapeutics reagents segment quantified using the revenue-capture definitions in the table below.

Estimation Model 

To learn more about this report, Download Free Sample Report

The study adopted an epidemiology-based market analysis approach to estimate the size of the global insomnia therapeutics market. Country level adult population data were evaluated to estimate the prevalence of acute and chronic insomnia using published epidemiological studies and government health databases. The diagnosed patient population was derived using diagnosis rates obtained from clinical literature and healthcare statistics. The treated patient pool was estimated by assessing prescription rates, treatment seeking behavior, and physician prescribing patterns across major markets. Patients were further segmented by therapeutic class, including benzodiazepines, nonbenzodiazepines, antidepressants, orexin receptor antagonists, melatonin receptor agonists, and other therapies. Average annual treatment cost was determined using product pricing, treatment duration, and dosing information obtained from company annual reports, regulatory documents, product labels, and healthcare databases. The market estimates were validated through primary interviews with sleep medicine specialists and industry participants.

Delivered Customizations

This report has been delivered with the following In-depth customizations